{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T11:52:35Z","timestamp":1792929155795,"version":"4.5.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T00:00:00Z","timestamp":1664323200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1053\/j.ajkd.2022.08.012","type":"journal-article","created":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T12:56:10Z","timestamp":1664542570000},"page":"281-293.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"title":["Clinical Pattern of Tolvaptan-Associated Liver Injury in Trial Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD): An Analysis of Pivotal Clinical Trials"],"prefix":"10.1053","volume":"81","author":[{"given":"David H.","family":"Alpers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James H.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine M.","family":"Hunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James W.","family":"Freston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicente E.","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenchyi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molly E.","family":"Hoke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharin E.","family":"Roth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas","family":"Westcott-Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvin","family":"Estilo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1053\/j.ajkd.2022.08.012_bib1","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1053\/j.ajkd.2015.07.037","article-title":"Autosomal dominant polycystic kidney disease: core curriculum 2016","volume":"67","author":"Chebib","year":"2016","journal-title":"Am J Kidney Dis"},{"issue":"25","key":"10.1053\/j.ajkd.2022.08.012_bib2","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease","volume":"367","author":"Torres","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"20","key":"10.1053\/j.ajkd.2022.08.012_bib3","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1056\/NEJMoa1710030","article-title":"Tolvaptan in later-stage autosomal dominant polycystic kidney disease","volume":"377","author":"Torres","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1053\/j.ajkd.2022.08.012_bib4","doi-asserted-by":"crossref","first-page":"803","DOI":"10.2215\/CJN.06300615","article-title":"Effect of tolvaptan in autosomal dominant polycystic kidney disease by CKD stage: results from the TEMPO 3:4 trial","volume":"11","author":"Torres","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"10.1053\/j.ajkd.2022.08.012_bib5","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/cpt.564","article-title":"Drug-induced liver injury: advances in mechanistic understanding that will inform risk management","volume":"101","author":"Mosedale","year":"2017","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1053\/j.ajkd.2022.08.012_bib6","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.mayocp.2013.09.016","article-title":"Drug-induced liver injury","volume":"89","author":"Leise","year":"2014","journal-title":"Mayo Clin Proc"},{"issue":"4","key":"10.1053\/j.ajkd.2022.08.012_bib7","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1055\/s-0029-1240002","article-title":"Epidemiology of idiosyncratic drug-induced liver injury","volume":"29","author":"Bell","year":"2009","journal-title":"Semin Liver Dis"},{"key":"10.1053\/j.ajkd.2022.08.012_bib8","series-title":"LiverTox: clinical and research information on drug-induced liver injury","year":"2022"},{"issue":"6","key":"10.1053\/j.ajkd.2022.08.012_bib9","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.jhep.2019.02.014","article-title":"EASL Clinical Practice Guidelines: drug-induced liver injury","volume":"70","year":"2019","journal-title":"J\u00a0Hepatol"},{"issue":"3","key":"10.1053\/j.ajkd.2022.08.012_bib10","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.yrtph.2012.05.016","article-title":"A\u00a0pre-marketing ALT signal predicts post-marketing liver safety","volume":"63","author":"Moylan","year":"2012","journal-title":"Regul Toxicol Pharmacol"},{"issue":"4","key":"10.1053\/j.ajkd.2022.08.012_bib12","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/pds.1210","article-title":"How can \u2018Hy\u2019s law\u2019 help the clinician?","volume":"15","author":"Senior","year":"2006","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"3","key":"10.1053\/j.ajkd.2022.08.012_bib13","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1093\/ndt\/gfx043","article-title":"Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial","volume":"33","author":"Torres","year":"2018","journal-title":"Nephrol Dial Transplant"},{"issue":"11","key":"10.1053\/j.ajkd.2022.08.012_bib14","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s40264-015-0327-3","article-title":"Clinical pattern of tolvaptan-associated liver injury in subjects with autosomal dominant polycystic kidney disease: analysis of clinical trials database","volume":"38","author":"Watkins","year":"2015","journal-title":"Drug Saf"},{"issue":"3","key":"10.1053\/j.ajkd.2022.08.012_bib15","doi-asserted-by":"crossref","first-page":"72","DOI":"10.4254\/wjh.v12.i3.72","article-title":"Polycystic liver disease: classification, diagnosis, treatment process, and clinical management","volume":"12","author":"Zhang","year":"2020","journal-title":"World J Hepatol"},{"issue":"1","key":"10.1053\/j.ajkd.2022.08.012_bib16","doi-asserted-by":"crossref","first-page":"48","DOI":"10.2215\/CJN.10250620","article-title":"Multicenter study of long-term safety of tolvaptan in later-stage autosomal dominant polycystic kidney disease","volume":"16","author":"Torres","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2022.08.012_bib17","series-title":"JYNARQUE [US package insert]","year":"2020"},{"issue":"3","key":"10.1053\/j.ajkd.2022.08.012_bib18","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1002\/hep.28353","article-title":"Can rechallenge be done safely after mild or moderate drug-induced liver injury?","volume":"63","author":"Senior","year":"2016","journal-title":"Hepatology"},{"issue":"2","key":"10.1053\/j.ajkd.2022.08.012_bib19","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1378\/chest.68.2.181","article-title":"Acetylation rates and monthly liver function tests during one year of isoniazid preventive therapy","volume":"68","author":"Mitchell","year":"1975","journal-title":"Chest"},{"issue":"1","key":"10.1053\/j.ajkd.2022.08.012_bib20","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2165\/00002018-200932010-00005","article-title":"Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct","volume":"32","author":"Fontana","year":"2009","journal-title":"Drug Saf"},{"issue":"6","key":"10.1053\/j.ajkd.2022.08.012_bib21","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1002\/hep.23577","article-title":"Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method","volume":"51","author":"Rockey","year":"2010","journal-title":"Hepatology"},{"issue":"suppl 1","key":"10.1053\/j.ajkd.2022.08.012_bib22","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1007\/s40264-014-0185-4","article-title":"Causality assessment for suspected DILI during clinical phases of drug development","volume":"37","author":"Regev","year":"2014","journal-title":"Drug Saf"},{"issue":"11","key":"10.1053\/j.ajkd.2022.08.012_bib23","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/0895-4356(93)90101-6","article-title":"Causality assessment of adverse reactions to drugs--I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries","volume":"46","author":"Danan","year":"1993","journal-title":"J\u00a0Clin Epidemiol"},{"issue":"3","key":"10.1053\/j.ajkd.2022.08.012_bib24","doi-asserted-by":"crossref","first-page":"243","DOI":"10.2165\/11586600-000000000-00000","article-title":"Evaluation of drug-induced serious hepatotoxicity (eDISH): application of this data organization approach to phase III clinical trials of rivaroxaban after total hip or knee replacement surgery","volume":"34","author":"Watkins","year":"2011","journal-title":"Drug Saf"},{"issue":"suppl 1","key":"10.1053\/j.ajkd.2022.08.012_bib25","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1007\/s40264-014-0182-7","article-title":"Evolution of the Food and Drug Administration approach to liver safety assessment for new drugs: current status and challenges","volume":"37","author":"Senior","year":"2014","journal-title":"Drug Saf"},{"issue":"3","key":"10.1053\/j.ajkd.2022.08.012_bib26","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/clpt.2008.262","article-title":"Monitoring for hepatotoxicity: what is the predictive value of liver \u201cfunction\u201d tests?","volume":"85","author":"Senior","year":"2009","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1053\/j.ajkd.2022.08.012_bib27","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/hep.23696","article-title":"Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop","volume":"52","author":"Fontana","year":"2010","journal-title":"Hepatology"},{"issue":"6","key":"10.1053\/j.ajkd.2022.08.012_bib28","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/clpt.2011.58","article-title":"Case definition and phenotype standardization in drug-induced liver injury","volume":"89","author":"Aithal","year":"2011","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1053\/j.ajkd.2022.08.012_bib29","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/hep.29152","article-title":"Drug rechallenge following drug-induced liver injury","volume":"66","author":"Hunt","year":"2017","journal-title":"Hepatology"},{"issue":"12","key":"10.1053\/j.ajkd.2022.08.012_bib30","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1093\/clinchem\/46.12.2027","article-title":"Diagnosis and monitoring of hepatic injury. I. Performance characteristics of laboratory tests","volume":"46","author":"Dufour","year":"2000","journal-title":"Clin Chem"},{"key":"10.1053\/j.ajkd.2022.08.012_bib31","doi-asserted-by":"crossref","first-page":"649","DOI":"10.2147\/TCRM.S286952","article-title":"Safety profile of tolvaptan in the treatment of autosomal dominant polycystic kidney disease","volume":"17","author":"Bellos","year":"2021","journal-title":"Ther Clin Risk Manag"},{"key":"10.1053\/j.ajkd.2022.08.012_bib32","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/j.1365-2125.2011.04114.x","article-title":"Effects of CYP3A4 inhibition and induction on the pharmacokinetics and pharmacodynamics of tolvaptan, a non-peptide AVP antagonist in healthy subjects","volume":"73","author":"Shoaf","year":"2012","journal-title":"Br J Clin Pharmacol"},{"key":"10.1053\/j.ajkd.2022.08.012_bib33","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1358\/dof.2002.027.04.668950","article-title":"Tolvaptan: treatment for heart failure vasopressin V2 antagonist","volume":"27","author":"Sorbera","year":"2002","journal-title":"Drugs Future"},{"key":"10.1053\/j.ajkd.2022.08.012_bib34","unstructured":"Tammara BK, Sekar KS, Brumer SL. The disposition of a single dose of 14C OPC-41061 in healthy male volunteers. Abstract presented at: 1999 American Association of Pharmaceutical Scientists Annual Meeting and Exposition; November 14-18, 1999; New Orleans, LA. Abstract\u00a02025."},{"key":"10.1053\/j.ajkd.2022.08.012_bib35","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1038\/ki.2013.350","article-title":"Pharmacokinetics and pharmacodynamics of oral tolvaptan in patients with varying degrees of renal function","volume":"85","author":"Shoaf","year":"2014","journal-title":"Kidney Int"},{"issue":"1","key":"10.1053\/j.ajkd.2022.08.012_bib36","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1093\/toxsci\/kfv231","article-title":"Inhibition of human hepatic bile acid transporters by tolvaptan and metabolites: contributing factors to drug-induced liver injury?","volume":"149","author":"Slizgi","year":"2016","journal-title":"Toxicol Sci"},{"issue":"1","key":"10.1053\/j.ajkd.2022.08.012_bib37","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1093\/toxsci\/kfw193","article-title":"Application of a mechanistic model to evaluate putative mechanisms of tolvaptan drug-induced liver injury and identify patient susceptibility factors","volume":"155","author":"Woodhead","year":"2017","journal-title":"Toxicol Sci"},{"issue":"3","key":"10.1053\/j.ajkd.2022.08.012_bib38","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1002\/hep.27206","article-title":"Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump","volume":"60","author":"Aleo","year":"2014","journal-title":"Hepatology"},{"key":"10.1053\/j.ajkd.2022.08.012_bib39","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1002\/hep.26208","article-title":"High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury","volume":"58","author":"Chen","year":"2013","journal-title":"Hepatology"},{"issue":"7","key":"10.1053\/j.ajkd.2022.08.012_bib40","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.3390\/ijms18071335","article-title":"Associations of drug lipophilicity and extent of metabolism with drug-induced liver injury","volume":"18","author":"McEuen","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1053\/j.ajkd.2022.08.012_bib41","series-title":"Tolvaptan","year":"2021"},{"issue":"3","key":"10.1053\/j.ajkd.2022.08.012_bib42","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1002\/hep.28678","article-title":"A\u00a0model to predict severity of drug-induced liver injury in humans","volume":"64","author":"Chen","year":"2016","journal-title":"Hepatology"},{"key":"10.1053\/j.ajkd.2022.08.012_bib43","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1124\/dmd.119.086785","article-title":"Altered expression and function of hepatic transporters in a rodent model of polycystic kidney disease","volume":"47","author":"Bezen\u00e7on","year":"2019","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"10.1053\/j.ajkd.2022.08.012_bib44","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/cpt.2007","article-title":"Quantitative systems toxicology modeling predicts that reduced biliary efflux contributes to tolvaptan hepatotoxicity","volume":"109","author":"Beaudoin","year":"2021","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1053\/j.ajkd.2022.08.012_bib45","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/liv.12988","article-title":"Mechanisms of adaptation and progression in idiosyncratic drug induced liver injury, clinical implications","volume":"36","author":"Dara","year":"2016","journal-title":"Liver Int"},{"issue":"2","key":"10.1053\/j.ajkd.2022.08.012_bib46","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/cpt.1571","article-title":"Next-generation DILI biomarkers: prioritization of biomarkers for qualification and best practices for biospecimen collection in drug development","volume":"107","author":"Roth","year":"2020","journal-title":"Clin Pharmacol Ther"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638622009210?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638622009210?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T03:48:13Z","timestamp":1759463293000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638622009210"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S0272638622009210"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2022.08.012","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.742350451.793597671","asserted-by":"object"}]},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Pattern of Tolvaptan-Associated Liver Injury in Trial Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD): An Analysis of Pivotal Clinical Trials","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2022.08.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}]}}